logo
Shock reason couple could be booted from Aus

Shock reason couple could be booted from Aus

Yahoo30-03-2025
A young British couple who met and fell in love in Australia has been left in limbo, fearing every day they could be given just 28 days to leave the country after one of them was diagnosed with an incurable disease.
Jessica Mathers, 30, and Robert O'Leary, 31, have called Sydney's eastern suburbs home for the last eight years and have settled in Bondi Junction.
The pair met in Sydney at a backpackers hostel in 2017 on separate working visas before moving out together to Kings Cross.
They decided to apply for a permanent residency visa in May of 2022.
But their application was rejected in 2023 due to Ms Mathers' ongoing health condition, leaving them 'completely in limbo' and facing deportation.
In 2020, Ms Mathers was diagnosed with Relapsing-Remitting Multiple Sclerosis (MS) and her condition has remained stable after receiving regular treatment under the Reciprocal Health Care Arrangement with their homeland (the UK).
'We've been struggling since my diagnosis,' she told NewsWire.
'The minute we applied for the next sponsorship in 2021 we were having to go through a whole new process because I now have a health condition that I declared.'
'It doesn't seem fair at all that you can be told to leave a place where you have built your life, your friends (and) your family have been to visit you,' Mr O'Leary said.
Ms Mathers was told she would have to wait six months for the Commonwealth Health Minister to review her sponsorship application.
'I lost jobs in probation because they just couldn't wait for me any longer,' Ms Mathers said.
'I used to be an agile project manager in e-commerce, I have a ten-year career, and now I'm doing temp receptionist roles.'
The couple expressed their frustration at the frozen state of their appeal, having not realised it would be 'such a fight'.
'Considering we're English, its Commonwealth – it's all covered under the reciprocal Medicare agreement at the present moment,' Ms Mathers said.
Mr O'Leary said he was 'definitely disappointed' in how their visa application was being handled by the Australian Government.
'It's down the lines of discrimination against us. If you worked for a company and they said 'oh we're going to let you go because you've got a health condition' – in this day and age there would be uproar,' he said.
'Three years on from (Ms Mathers' diagnosis) we were declined because Jess had a health condition, which is kind of that same factor of being told you can't remain because of a health condition you were diagnosed with when you lived here.'
Ms Mathers' condition has not stopped her from working as normal and contributing to the community. She currently works in a temporary position at a North Sydney law firm and DJs up to 12 hours on weekends.
Alongside this, she has participated in clinical trials for MS and actively raises awareness for the condition – work which got her nominated for the 'Bondi Creative Woman of the Year' award.
Mr O'Leary owns his own construction business – O'Leary Cranes and Construction – and works as a carpenter, exceeding the 80 points required on his visa by attaining 110.
Despite the couple spending close to a decade working as skilled migrants in Australia and paying taxes, the government rejected their permanent residency application, citing the potential future costs of Jessica's condition.
The couple are currently awaiting their appeal before the Administrative Appeals Tribunal (AAT). If they fail in their case, they will be given 28 days to leave the country.
'We could get the appeal date tomorrow, there's no way of knowing, it could be next year but it could be tomorrow,' Mr O'Leary said.
'Twenty-eight days to effectively pack up your life, say goodbye to your friends – like you won't be able to come back, not even as a visitor. So it's see you later, you're never coming back, your life here ceases to exist … That would be heartbreaking,' Mr O'Leary said.
'We've met here. It's where we've always been. We've been living together for eight years now,' Ms Mathers said. 'Our whole life is Sydney.'
To gain support for their fight, Ms Mathers and Mr O'Leary have organised a change.org petition titled 'Please do not deport me and my partner, because she was diagnosed with a health condition'.
They currently have 1815 signatures and are asking for the Minister for Home Affairs to review their case and 'make changes to the immigration policies that unfairly target individuals with well-managed health conditions', the petition reads.
'We're trying to do something to help our situation before it reaches the final points – it might actually make a real difference,' Mr O'Leary said.
The couple hopes that their eight years of contributions to the Aussie community, economy and society is enough to grant them permanent residency in the place they call home.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug

Yahoo

time2 hours ago

  • Yahoo

Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug

Quantum Biopharma Ltd. (NASDAQ:QNTM) announced on Tuesday that its subsidiary Huge Biopharma Australia has received the clinical study report for a Phase 1, randomized, double-blind, placebo-controlled multiple ascending dose trial evaluating the safety and pharmacokinetics of Lucid-MS in healthy adults. The report confirms that daily dosing of Lucid-MS posed no safety or tolerability concerns, clearing a critical regulatory milestone and supporting the compound's advancement. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibers. "The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug (IND) application with the FDA," said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma. "Results and observations from the first-in-human studies including this MAD investigation give us the confidence that Lucid-MS is safe and tolerable in healthy volunteers," noted Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and Professor at the University of Toronto, who led the discovery of the compound. According to Benzinga Pro, QNTM stock has gained over 388% in the past year. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF (NYSE:PSIL). Price Action: At last check Tuesday, QNTM shares were trading lower by 8.63% to $25.40. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Miami Herald

time10 hours ago

  • Miami Herald

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to Erase MS and Cure Addiction Now foundations, to its Board of Directors. Ms. Davis brings an unparalleled fusion of deep-seated patient advocacy, strategic fundraising, and a profound, personal commitment to accelerating scientific discovery in areas of critical unmet medical need. Her decades of consummate resilience and unwavering patient-centric approach, born from personal experience, make her an ideal and impactful addition to the Board. Ms. Davis's formidable journey into medical advocacy was ignited by her own diagnosis of multiple sclerosis (MS) in 1991, at the age of 33. Despite being told there was little hope, Nancy refused to accept this prognosis, proactively seeking new therapies and embracing a health-conscious lifestyle. This deeply personal challenge fueled her determination to fundamentally transform the landscape of MS research and treatment. In 1993, she established the Race to Erase MS, an organization that has since raised over $56 million, directly catalyzing groundbreaking research through its innovative "Center Without Walls" program. This pioneering initiative actively dismantles traditional research silos, fostering unprecedented collaboration among leading institutions such as UC San Francisco, Harvard, Yale, USC, Johns Hopkins, UCLA, Cedars-Sinai, and Oregon Health Sciences University. Under her visionary leadership, Race to Erase MS has funded numerous pilot studies instrumental in developing FDA-approved therapies, including the scientific discoveries in B-Cell therapies like Ocrevus®, Briumvi®, and Kesimpta®, which are now gold standards of MS treatment and have completely changed the landscape of the disease. When Nancy founded the organization, there were no FDA-approved treatments for MS but her guiding principle, "take the impossible and make it possible," perfectly encapsulates her profound impact. "Tharimmune is incredibly honored and privileged to welcome Nancy Davis to our Board," said Vincent LoPriore, Executive Chairman of the Board of Director. "Nancy's extraordinary dedication to advancing medical research, coupled with her unique and powerful perspective as both a patient advocate and a formidable force for scientific collaboration, is absolutely invaluable as we continue to develop innovative, life-saving therapies. Her vision aligns perfectly with our mission to bring life-changing solutions to patients, especially as we advance our investigational product, TH104. Our lead is being specifically developed to counter the effects of weaponized fentanyl for military use and chemical incident responders, and it may potentially hold significant promise for broader applications in addressing the devastating opioid crisis. Nancy's profound understanding of patient needs and her unwavering commitment to finding solutions for addiction make her an indispensable and critical voice on our Board. Her proven track record of converting personal adversity into global advocacy and tangible scientific progress is truly inspiring." Ms. Davis co-founded Cure Addiction Now (CAN) with her son, Jason and this pivotal foundation is dedicated to revolutionizing the understanding and treatment of substance use disorder (SUD) by funding cutting-edge, collaborative research that addresses both the physical and emotional aspects of addiction. CAN aims to find therapies that combat withdrawal and cravings, with the ultimate goal of achieving lasting sobriety. Her transformative work with CAN continues to fiercely challenge stigmas and relentlessly push for scientific breakthroughs to combat one of the most pressing public health crises of our time. "I am thrilled and deeply motivated to join the Board of Directors at Tharimmune and contribute to their ongoing, exciting work," said Nancy Davis. "Throughout my career, I've seen firsthand the profound power of focused, collaborative scientific endeavor to bring about real, tangible change for patients. I am deeply impressed by Tharimmune's commitment to developing critical countermeasures, such as TH104. My personal experiences with the devastating impact of addiction have only strengthened my resolve to support truly innovative solutions and I eagerly look forward to contributing my insights and advocacy to help accelerate the development and potential broader impact of this solution and other transformative therapies." About Tharimmune, is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contacts:Tharimmune, SOURCE: Tharimmune Inc.

High Lp(a) Signals Risk Beyond The Coronaries
High Lp(a) Signals Risk Beyond The Coronaries

Medscape

time15 hours ago

  • Medscape

High Lp(a) Signals Risk Beyond The Coronaries

TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary athero­sclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store